Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

AbbVie’s zumilokibart meets phase 2 atopic dermatitis endpoint

AbbVie’s zumilokibart meets phase 2 atopic dermatitis endpoint

We haven't written up this one. Investing.com has the full story — the link below goes straight to it.

Also reported by 2 other outlets

Read the original at investing.com →

More in Finance & Markets

More from Wednesday 30 September →